[3]de Bernardi A, Bachelot T, Larrouquère L. Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature. Front Oncol. 2024 Jan 10;13:1...
trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 14(6):461–71. doi:...
[10] Yan M, Bian L, Hu XC, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1:13. [1...
1、Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. Int J Clin Oncol. 2022 Feb;27(2):332-339. 2、Junji Tsurutani, et al. Subgroup Analysis of Patients ...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. ...
de Bernardi A, Bachelot T and Larrouquère L (2024) Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature. Front. Oncol. 13:1210873...
10、Hurvitz,Sara A et al.“HER2CLIMB-02:Randomized,double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer.”2023 SABCS Abstract GS01-10. 11、Santiago Escrivá-de-Romani,et al.“Primary results from a phase 2a study of zani...
[17] Wang T, Zhang P , Di LJ,et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study. Transl Breast Cancer Res 2022 ...
Effectiveness and safety of inetetamab + pyrotinib + vinorelbine in ≥second-line treatment of HER2-positive metastatic breast cancer 研究背景 HER2过表达是乳腺癌预后不良的独立因素之一,也是抗HER2靶向治疗疗效的预测因素之一,占乳腺癌患者的20%～25%。目前多西他赛联合曲妥珠单抗和帕妥珠单抗仍是HER2阳性MBC...
Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet ...